Effectiveness of A Hemodynamic-Guided Treatment Strategy to Improve Blood Pressure Control
Primary Purpose
Hypertension
Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
ICG-guided drug selection
empirical drug selection
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring Hypertension, ICG-guided, Hemodynamic profiling, Impedance cardiography
Eligibility Criteria
Inclusion Criteria:
- office BP >= 140/90 mmHg
- hypertensive patients who were treatment naive or previously treated with 1-3 anti-hypertensives
- age 18-85, males or females
- agree to sign informed consent
Exclusion Criteria:
- having unstable hemodynamics diseases, or had myocardial infarction (MI), heart failure (HF) or chronic kidney disease (CKD) within previous 6 months
- using large doses of diuretics or beta-blockers (usually refers to double max doses) and can not stop dosing
- atrial fibrillation (AF) or severe arrhythmia
- severe aortic regurgitation
- severe thoracic fluids
- height weight out of ranges: 120-230 cm30-230 kg
- using more than 3 antihypertensives
- known secondary hypertension
- refused to sign informed consent
Sites / Locations
- Peking University People's Hospital
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
ICG-guided
Empirical
Arm Description
anti-hypertensive drug selection based on physician's experience and hemodynamic profiling by measured ICG
anti-hypertensive drug selection based on physician's experience only
Outcomes
Primary Outcome Measures
Change from baseline systolic blood pressure at 8 weeks
Change from baseline systolic blood pressure at 8 weeks in the window of 4-12 weeks
Change from baseline diastolic blood pressure at 8 weeks
Change from baseline diastolic blood pressure at 8 weeks in the window of 4-12
Secondary Outcome Measures
BP control rate at 8 weeks
proportion of subjects with BP < 140/90 mmHg at 8 weeks post-baseline visit
Change from baseline heart rate (HR) at 8 weeks
Change from baseline heart rate (heart beats per minute) at 8 weeks in the window of 4-12 weeks
Change from baseline cardiac index (CI) at 8 weeks
Change from baseline cardiac index (cardiac output devided by body surface area) at 8 weeks in the window of 4-12 weeks
Change from baseline arterial stiffness (AS) at 8 weeks
Change from baseline arterial stiffness at 8 weeks in the window of 4-12 weeks
Change from baseline systemic vascular resistance index (SVRI) at 8 weeks
Change from baseline systemic vascular resistance index at 8 weeks in the window of 4-12 weeks
Change from baseline thoracic blood volume standing/supine ratio (TBR) at 8 weeks
Change from baseline thoracic blood volume standing vs supine ratio at 8 weeks in the window of 4-12 weeks
Full Information
NCT ID
NCT04715698
First Posted
January 11, 2021
Last Updated
January 16, 2021
Sponsor
Peking University People's Hospital
Collaborators
Yale University, Shanghai Jiao Tong University School of Medicine
1. Study Identification
Unique Protocol Identification Number
NCT04715698
Brief Title
Effectiveness of A Hemodynamic-Guided Treatment Strategy to Improve Blood Pressure Control
Official Title
Effectiveness of A Hemodynamic-Guided Treatment Strategy to Improve Blood Pressure Control
Study Type
Interventional
2. Study Status
Record Verification Date
January 2021
Overall Recruitment Status
Completed
Study Start Date
December 31, 2018 (Actual)
Primary Completion Date
December 31, 2019 (Actual)
Study Completion Date
December 31, 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Peking University People's Hospital
Collaborators
Yale University, Shanghai Jiao Tong University School of Medicine
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
A single-center, single-blind, randomized study to investigate the effectiveness of a hemodynamic-guided treatment strategy to improve blood pressure control
Detailed Description
Hypertension is a hemodynamic-related disorder characterized by abnormalities of the cardiac output (CO) and/or systemic vascular resistance (SVR). It is hypothesized that selecting antihypertensive therapy based on patients' hemodynamic profile could lead to more effective blood pressure (BP) control than standard care in a real-world population of hypertensive patients in outpatient setting. A single-center, randomized trial was conducted to include adults with uncontrolled hypertension who seek outpatient care at Peking University People's Hospital between December 2018 and December 2019 in Beijing, China.
Participants were randomly assigned to the standard care group or the hemodynamic group in a 1:1 ratio. Impedance cardiography (ICG) was performed with all participants to measure hemodynamic parameters. Only physicians in the hemodynamic group were provided with patients' ICG findings and a computerized clinical decision support of recommended treatment choices based on patients' hemodynamic profiles. The primary outcomes were the reductions in systolic BP (SBP) and diastolic BP (DBP) levels at the follow-up visit 8(±4) weeks after baseline. Secondary outcomes included achievement of BP goal of <140/ 90 mmHg and the reductions in BP by baseline BP, age, sex, and BMI.
The ICG device used (HDproTM CHM T3002/P3005, designed by Beijing Li-Heng Medical Technologies, Ltd, manufactured by Shandong Baolihao Medical Appliances, Ltd.) was developed based on improved hardware and advanced digital filtering algorithms, and has been validated versus both invasive thermodilution and non-invasive echocardiography in different settings.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
Hypertension, ICG-guided, Hemodynamic profiling, Impedance cardiography
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
102 (Actual)
8. Arms, Groups, and Interventions
Arm Title
ICG-guided
Arm Type
Experimental
Arm Description
anti-hypertensive drug selection based on physician's experience and hemodynamic profiling by measured ICG
Arm Title
Empirical
Arm Type
Active Comparator
Arm Description
anti-hypertensive drug selection based on physician's experience only
Intervention Type
Other
Intervention Name(s)
ICG-guided drug selection
Intervention Description
anti-hypertensive drug selection based on patient's hemodynamic profiling and physician's experience
Intervention Type
Other
Intervention Name(s)
empirical drug selection
Intervention Description
anti-hypertensive drug selection based on physician's experience only
Primary Outcome Measure Information:
Title
Change from baseline systolic blood pressure at 8 weeks
Description
Change from baseline systolic blood pressure at 8 weeks in the window of 4-12 weeks
Time Frame
8 weeks post-baseline
Title
Change from baseline diastolic blood pressure at 8 weeks
Description
Change from baseline diastolic blood pressure at 8 weeks in the window of 4-12
Time Frame
8 weeks post-baseline
Secondary Outcome Measure Information:
Title
BP control rate at 8 weeks
Description
proportion of subjects with BP < 140/90 mmHg at 8 weeks post-baseline visit
Time Frame
8 weeks post-baseline
Title
Change from baseline heart rate (HR) at 8 weeks
Description
Change from baseline heart rate (heart beats per minute) at 8 weeks in the window of 4-12 weeks
Time Frame
8 weeks post-baseline
Title
Change from baseline cardiac index (CI) at 8 weeks
Description
Change from baseline cardiac index (cardiac output devided by body surface area) at 8 weeks in the window of 4-12 weeks
Time Frame
8 weeks post-baseline
Title
Change from baseline arterial stiffness (AS) at 8 weeks
Description
Change from baseline arterial stiffness at 8 weeks in the window of 4-12 weeks
Time Frame
8 weeks post-baseline
Title
Change from baseline systemic vascular resistance index (SVRI) at 8 weeks
Description
Change from baseline systemic vascular resistance index at 8 weeks in the window of 4-12 weeks
Time Frame
8 weeks post-baseline
Title
Change from baseline thoracic blood volume standing/supine ratio (TBR) at 8 weeks
Description
Change from baseline thoracic blood volume standing vs supine ratio at 8 weeks in the window of 4-12 weeks
Time Frame
8 weeks post-baseline
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
85 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
office BP >= 140/90 mmHg
hypertensive patients who were treatment naive or previously treated with 1-3 anti-hypertensives
age 18-85, males or females
agree to sign informed consent
Exclusion Criteria:
having unstable hemodynamics diseases, or had myocardial infarction (MI), heart failure (HF) or chronic kidney disease (CKD) within previous 6 months
using large doses of diuretics or beta-blockers (usually refers to double max doses) and can not stop dosing
atrial fibrillation (AF) or severe arrhythmia
severe aortic regurgitation
severe thoracic fluids
height weight out of ranges: 120-230 cm30-230 kg
using more than 3 antihypertensives
known secondary hypertension
refused to sign informed consent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Ningling Sun
Organizational Affiliation
Department of Hypertension at Heart Centr, Peking University People's Hospital, Beijing, China
Official's Role
Principal Investigator
Facility Information:
Facility Name
Peking University People's Hospital
City
Beijing
Country
China
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
34580169
Citation
Lu Y, Wang L, Wang H, Gu J, Ma ZJ, Lian Z, Zhang Z, Krumholz H, Sun N. Effectiveness of an impedance cardiography guided treatment strategy to improve blood pressure control in a real-world setting: results from a pragmatic clinical trial. Open Heart. 2021 Sep;8(2):e001719. doi: 10.1136/openhrt-2021-001719. Erratum In: Open Heart. 2021 Oct;8(2): Open Heart. 2021 Nov;8(2):
Results Reference
derived
Learn more about this trial
Effectiveness of A Hemodynamic-Guided Treatment Strategy to Improve Blood Pressure Control
We'll reach out to this number within 24 hrs